1. Home
  2. BNR vs XLO Comparison

BNR vs XLO Comparison

Compare BNR & XLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BNR
  • XLO
  • Stock Information
  • Founded
  • BNR 2014
  • XLO 2016
  • Country
  • BNR China
  • XLO United States
  • Employees
  • BNR N/A
  • XLO N/A
  • Industry
  • BNR Medical Specialities
  • XLO Biotechnology: Pharmaceutical Preparations
  • Sector
  • BNR Health Care
  • XLO Health Care
  • Exchange
  • BNR Nasdaq
  • XLO Nasdaq
  • Market Cap
  • BNR 38.3M
  • XLO 41.3M
  • IPO Year
  • BNR 2020
  • XLO 2021
  • Fundamental
  • Price
  • BNR $12.25
  • XLO $0.83
  • Analyst Decision
  • BNR
  • XLO Buy
  • Analyst Count
  • BNR 0
  • XLO 2
  • Target Price
  • BNR N/A
  • XLO $3.00
  • AVG Volume (30 Days)
  • BNR 33.9K
  • XLO 711.6K
  • Earning Date
  • BNR 12-02-2025
  • XLO 11-07-2025
  • Dividend Yield
  • BNR N/A
  • XLO N/A
  • EPS Growth
  • BNR N/A
  • XLO N/A
  • EPS
  • BNR N/A
  • XLO N/A
  • Revenue
  • BNR $74,862,782.00
  • XLO $15,001,000.00
  • Revenue This Year
  • BNR $136.32
  • XLO $519.70
  • Revenue Next Year
  • BNR N/A
  • XLO $44.57
  • P/E Ratio
  • BNR N/A
  • XLO N/A
  • Revenue Growth
  • BNR 5.20
  • XLO 536.45
  • 52 Week Low
  • BNR $2.18
  • XLO $0.62
  • 52 Week High
  • BNR $13.89
  • XLO $1.70
  • Technical
  • Relative Strength Index (RSI)
  • BNR 60.87
  • XLO 56.54
  • Support Level
  • BNR $11.31
  • XLO $0.79
  • Resistance Level
  • BNR $12.71
  • XLO $0.88
  • Average True Range (ATR)
  • BNR 1.04
  • XLO 0.06
  • MACD
  • BNR 0.09
  • XLO 0.00
  • Stochastic Oscillator
  • BNR 72.11
  • XLO 60.61

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.

About XLO Xilio Therapeutics Inc.

Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.

Share on Social Networks: